KDEV Karolinska Development AB

Karolinska Developments portföljbolag Aprea Therapeutics erhåller FDA-godkännande för att inleda fas 1-studie av APR-548

Karolinska Developments portföljbolag Aprea Therapeutics erhåller FDA-godkännande för att inleda fas 1-studie av APR-548
EN
07/10/2020

Underlying

KDEVKarolinska Development AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Karolinska Development AB

 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development receives update from Organon concerning OG-6219

Karolinska Development receives update from Organon concerning OG-6219 STOCKHOLM, SWEDEN – July 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces an update from Organon on the development of the drug candidate OG-6219, acquired by Organon through its acquisition of Forendo Pharma in 2021. Following results from a Phase 2 clinical study with OG-6219, Organon plans to discontinue the clinical development of the drug candidate. Organon has announced results from the Phase 2 ELENA proof-of-concept, where the drug candidate OG-6219 was evaluated in patients with endom...

21h / 5m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development får uppdatering från Organon gällande OG-6219

Karolinska Development får uppdatering från Organon gällande OG-6219 STOCKHOLM, 3 juli 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolaget mottagit en uppdatering från Organon gällande utvecklingen av läkemedelskandidaten OG-6219, som förvärvades av Organon genom uppköpet av Forendo Pharma 2021. Till följd av resultat från en klinisk fas 2-studie med OG-6219 planerar Organon att avsluta det kliniska utvecklingsprogrammet med OG-6219. Organon har meddelat resultat från den kliniska fas 2-studien ELENA, en proof-of-concept-studie som utvärderade läkemedelskandidaten...

21h / 5m 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development divests shares in portfolio company OssDsign

Karolinska Development divests shares in portfolio company OssDsign STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company’s liquidity. The divestments brings Karolinska Development a capital injection of approximately SEK 34.5 million. Karolinska Development has been a long-term owner of OssDsign and was involved in the listing of the company on Nasdaq First North Growth Market in Stockholm in 2019. "We have been on a long journey with OssDsign and s...

June 30, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development avyttrar aktier i portföljbolaget OssDsign

Karolinska Development avyttrar aktier i portföljbolaget OssDsign STOCKHOLM, SVERIGE 30 juni 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) avyttrar resterande aktier i portföljbolaget OssDsign och stärker därmed investmentbolagets likviditet. Avyttringen tillför Karolinska Development ett kapitaltillskott på nära 34,5 miljoner kronor. Karolinska Development har varit en långsiktig ägare i OssDsign och var med och introducerade bolaget på Nasdaq First North Growth Market i Stockholm under 2019. ”Vi har varit med på en lång resa med OssDsign och stöttat bolaget genom flera viktig...

June 30, 2025 1 EN
 PRESS RELEASE
Free
KDEV Karolinska Deve...

Karolinska Development's portfolio company Modus Therapeutics carries ...

Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million STOCKHOLM, SWEDEN June 27, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia. On June 26 2025, the portfolio company Modus Therapeutics, listed on Nasdaq First North Growth Mark...

June 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch